GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Beginning Cash Position

Contineum Therapeutics (Contineum Therapeutics) Beginning Cash Position : $15.53 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Beginning Cash Position?

Contineum Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2024 was $15.53 Mil.

Contineum Therapeutics's quarterly Beginning Cash Position increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($17.52 Mil) but then declined from Dec. 2023 ($17.52 Mil) to Mar. 2024 ($15.53 Mil).

Contineum Therapeutics's annual Beginning Cash Position declined from Dec. 2021 ($16.03 Mil) to Dec. 2022 ($4.63 Mil) but then increased from Dec. 2022 ($4.63 Mil) to Dec. 2023 ($5.57 Mil).

Contineum Therapeutics Beginning Cash Position Historical Data

The historical data trend for Contineum Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Beginning Cash Position Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Beginning Cash Position
16.03 4.63 5.57

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Beginning Cash Position Get a 7-Day Free Trial 5.35 5.57 - 17.52 15.53

Contineum Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Contineum Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics (Contineum Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Beginning Cash Position
Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Website
https://www.contineum-tx.com
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus

Contineum Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire • 04-05-2024